Amarin's (NASDAQ: AMRN) new triglyceride-lowering drug Vascepa may or may not be a blockbuster when it hits the market. Vascepa's active ingredients are derived from omega-3 fatty acids found in fish oils, as are the active ingredients in Lovaza. This drug, which is sold by pharma giant GlaxoSmithKline (NYSE: GSK), generated more than $900 million in sales last year and will be Vascepa's biggest competition.
Recently, one of Amarin's suppliers -- German chemical company BASF (NASDAQOTH:BASFY) -- announced its intention to acquire a company called Pronova BioPharma, which actually produces Lovaza for GlaxoSmithKline.
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss this deal and its potential impact on investors.